Literature DB >> 20305140

Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation.

Désirée Caselli1, Simone Cesaro, Ottavio Ziino, Giulio Zanazzo, Rosaria Manicone, Susanna Livadiotti, Monica Cellini, Stefano Frenos, Giuseppe M Milano, Barbara Cappelli, Maria Licciardello, Chiara Beretta, Maurizio Aricò, Elio Castagnola.   

Abstract

Pseudomonas aeruginosa is one leading gram-negative organism associated with nosocomial infections. Bacteremia is life-threatening in the immunocompromised host. Increasing frequency of multi-drug-resistant (MDRPA) strains is concerning. We started a retrospective survey in the pediatric hematology oncology Italian network. Between 2000 and 2008, 127 patients with Pseudomonas aeruginosa bacteremia were reported from 12 centers; 31.4% of isolates were MDRPA. Death within 30 days of a positive blood culture occurred in 19.6% (25/127) of total patients; in patients with MDRPA infection it occurred in 35.8% (14/39). In the multivariate analysis, only MDRPA had significant association with infection-related death. This is the largest series of Pseudomonas aeruginosa bacteremia cases from pediatric hematology oncology centers. Monitoring local bacterial isolates epidemiology is mandatory and will allow empiric antibiotic therapy to be tailored to reduce fatalities.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20305140      PMCID: PMC2930967          DOI: 10.3324/haematol.2009.020867

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  23 in total

1.  Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa.

Authors:  Y Carmeli; N Troillet; A W Karchmer; M H Samore
Journal:  Arch Intern Med       Date:  1999-05-24

2.  Cost of Gram-negative resistance.

Authors:  Heather L Evans; Shayna N Lefrak; Jason Lyman; Robert L Smith; Tae W Chong; Shannon T McElearney; Alison R Schulman; Michael G Hughes; Daniel P Raymond; Timothy L Pruett; Robert G Sawyer
Journal:  Crit Care Med       Date:  2007-01       Impact factor: 7.598

3.  Impact of antibiotic-resistant Gram-negative bacilli infections on outcome in hospitalized patients.

Authors:  Daniel P Raymond; Shawn J Pelletier; Traves D Crabtree; Heather L Evans; Timothy L Pruett; Robert G Sawyer
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

Review 4.  Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.

Authors:  Marilee D Obritsch; Douglas N Fish; Robert MacLaren; Rose Jung
Journal:  Pharmacotherapy       Date:  2005-10       Impact factor: 4.705

5.  Multiresistant Pseudomonas aeruginosa in a pediatric cystic fibrosis center: natural history and implications for segregation.

Authors:  G Davies; D McShane; J C Davies; A Bush
Journal:  Pediatr Pulmonol       Date:  2003-04

6.  Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia.

Authors:  Regina B Osih; Jessina C McGregor; Shayna E Rich; Anita C Moore; Jon P Furuno; Eli N Perencevich; Anthony D Harris
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

Review 7.  Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.

Authors:  N Mesaros; P Nordmann; P Plésiat; M Roussel-Delvallez; J Van Eldere; Y Glupczynski; Y Van Laethem; F Jacobs; P Lebecque; A Malfroot; P M Tulkens; F Van Bambeke
Journal:  Clin Microbiol Infect       Date:  2007-01-31       Impact factor: 8.067

8.  Overview of nosocomial infections caused by gram-negative bacilli.

Authors:  Robert Gaynes; Jonathan R Edwards
Journal:  Clin Infect Dis       Date:  2005-08-16       Impact factor: 9.079

9.  Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa.

Authors:  Stephen Osmon; Suzanne Ward; Victoria J Fraser; Marin H Kollef
Journal:  Chest       Date:  2004-02       Impact factor: 9.410

10.  Pseudomonas aeruginosa bacteremia in immunocompromised children: analysis of factors associated with a poor outcome.

Authors:  J E Fergie; S J Shema; L Lott; R Crawford; C C Patrick
Journal:  Clin Infect Dis       Date:  1994-03       Impact factor: 9.079

View more
  32 in total

1.  Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies.

Authors:  Enrico Maria Trecarichi; Mario Tumbarello; Morena Caira; Anna Candoni; Chiara Cattaneo; Domenico Pastore; Rosa Fanci; Annamaria Nosari; Nicola Vianelli; Alessandro Busca; Antonio Spadea; Livio Pagano
Journal:  Haematologica       Date:  2011-01       Impact factor: 9.941

2.  Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients.

Authors:  D Averbuch; E Horwitz; J Strahilevitz; P Stepensky; N Goldschmidt; M E Gatt; M Y Shapira; I B Resnick; D Engelhard
Journal:  Infection       Date:  2013-05-08       Impact factor: 3.553

3.  Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients.

Authors:  Piergiorgio Cojutti; Natalia Maximova; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

4.  Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa.

Authors:  Pier Giorgio Cojutti; Natalia Maximova; Giulia Schillani; William Hope; Federico Pea
Journal:  J Antimicrob Chemother       Date:  2019-06-01       Impact factor: 5.790

5.  Pseudomonas aeruginosa thiol peroxidase protects against hydrogen peroxide toxicity and displays atypical patterns of gene regulation.

Authors:  Nawarat Somprasong; Thichakorn Jittawuttipoka; Jintana Duang-Nkern; Adisak Romsang; Pimchai Chaiyen; Herbert P Schweizer; Paiboon Vattanaviboon; Skorn Mongkolsuk
Journal:  J Bacteriol       Date:  2012-05-18       Impact factor: 3.490

6.  European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Authors:  Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

7.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

8.  Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.

Authors:  C Gudiol; A Albasanz-Puig; J Laporte-Amargós; N Pallarès; A Mussetti; I Ruiz-Camps; P Puerta-Alcalde; E Abdala; C Oltolini; M Akova; M Montejo; M Mikulska; P Martín-Dávila; F Herrera; O Gasch; L Drgona; H Paz Morales; A-S Brunel; E García; B Isler; W V Kern; I Morales; G Maestro-de la Calle; M Montero; S S Kanj; O R Sipahi; S Calik; I Márquez-Gómez; J I Marin; M Z R Gomes; P Hemmatti; R Araos; M Peghin; J L Del Pozo; L Yáñez; R Tilley; A Manzur; A Novo; J Carratalà
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 9.  Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance.

Authors:  E Montassier; E Batard; T Gastinne; G Potel; M F de La Cochetière
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-25       Impact factor: 3.267

10.  Prognostic factors and scoring model of hematological malignancies patients with bloodstream infections.

Authors:  Yishu Tang; Qian Cheng; Qing Yang; Jing Liu; Di Zhang; Wei Cao; Qingxia Liu; Tianyi Zhou; Huiqi Zeng; Li Zhou; QinJin Wang; Huan Wei; Xin Li
Journal:  Infection       Date:  2018-05-16       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.